专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4892733A Biodegradable synthesis polypeptide and its therapeutic use 失效
标题翻译：可生物降解的合成多肽及其治疗用途
公开(公告)号：US4892733A
公开(公告)日：1990-01-09
申请号：US101298
申请日：1987-08-18
申请人： Daniel Bichon , Bernard Lamy , William Borloz
发明人： Daniel Bichon , Bernard Lamy , William Borloz
IPC分类号： A61K9/20 , A61K9/22 , A61K47/34 , A61K47/48 , A61L15/00 , A61L26/00 , A61L27/18 , A61L27/46 , A61L27/58 , C08G69/10 , C08G73/10
CPC分类号： C08G69/10 , A61K47/34 , A61K47/48315 , A61K9/2045 , A61L27/18 , A61L27/46 , A61L27/58
摘要： Derivatives of polyaspartic and/or polyglutamic acids whose side chains bear COOH groups capable to cyclize into anhydride. These polyacids and anhydrides can be used to manufacture medicines.
摘要翻译： PCT No.PCT / CH86 / 00177 Sec。 371日期1987年8月18日 102（e）1987年8月18日PCT 1986年12月15日PCT PCT。第WO87 / 03891号公报日期1987年7月2日。聚天冬氨酸和/或聚谷氨酸的衍生物，其侧链具有能够环化成酸酐的COOH基团。这些多酸和酸酐可用于制造药物。

2. 发明授权

US4976962A Biodegradable polypeptide and the use thereof for the gradual release of drugs 失效
标题翻译：可生物降解的多肽及其用于逐渐释放药物的用途
公开(公告)号：US4976962A
公开(公告)日：1990-12-11
申请号：US378072
申请日：1989-07-11
申请人： Daniel Bichon , Bernard Lamy
发明人： Daniel Bichon , Bernard Lamy
IPC分类号： C08G69/00 , A61K9/20 , A61K9/52 , A61K38/00 , A61K47/00 , A61K47/42 , A61L17/00 , A61L27/00 , A61L27/18 , A61L27/54 , A61L33/00 , C07K1/113 , C07K14/00 , C07K19/00 , C08G69/10 , C08G69/36 , C08G69/48 , C08G73/10 , C08J9/26 , C08K3/00 , C08L77/00 , C08L77/04
CPC分类号： C08G73/1092 , A61K9/2045 , A61L27/18 , A61L27/54 , C08G69/10 , A61L2300/00 , Y10S514/963 , Y10S514/964 , Y10S514/965
摘要： Biodegradable alkyloxycarbonylmethyl or aryloxycarbonylmethyl polyaspartate and polyglutamate which can be used as a carrier for drugs which are either in the encapsulated state or are incorporated in the polymer matrix. The polypeptide thus loaded degrades enzymatically in the organ where it has been placed and thus gradually releases the drug which it contains.

3. 发明授权

US4888398A Biodegradable polypeptide and the use thereof for the gradual release of drugs 失效
标题翻译：可生物降解的多肽及其用于逐渐释放药物的用途
公开(公告)号：US4888398A
公开(公告)日：1989-12-19
申请号：US788408
申请日：1985-10-17
申请人： Daniel Bichon , Bernard Lamy
发明人： Daniel Bichon , Bernard Lamy
IPC分类号： C08G69/00 , A61K9/20 , A61K9/52 , A61K38/00 , A61K47/00 , A61K47/42 , A61L17/00 , A61L27/00 , A61L27/18 , A61L27/54 , A61L33/00 , C07K1/113 , C07K14/00 , C07K19/00 , C08G69/10 , C08G69/36 , C08G69/48 , C08G73/10 , C08J9/26 , C08K3/00 , C08L77/00 , C08L77/04
CPC分类号： C08G73/1092 , A61K9/2045 , A61L27/18 , A61L27/54 , C08G69/10 , A61L2300/00 , Y10S514/963 , Y10S514/964 , Y10S514/965
摘要： Biodegradable alkyloxycarbonylmethyl or aryloxycarbonylmethyl polyaspartate and polyglutamate which can be used as a carrier for drugs which are either in the encapsulated state or are incorporated in the polymer matrix. The polypeptide thus loaded degrades enzymatically in the organ where it has been placed and thus gradually releases the drug which it contains.
摘要翻译：可生物降解的烷氧基羰基甲基或芳氧基羰基甲基聚天冬氨酸盐和聚谷氨酸盐，其可以用作处于封装状态或掺入聚合物基质中的药物的载体。如此加载的多肽在被放置的器官中酶促降解，从而逐渐释放其所含的药物。

4. 发明授权

US07985402B2 Targeting vector-phospholipid conjugates 有权
标题翻译：靶向载体 - 磷脂缀合物
公开(公告)号：US07985402B2
公开(公告)日：2011-07-26
申请号：US11954130
申请日：2007-12-11
申请人： Philippe Bussat , Samir Cherkaoui , Hong (Helen) Fan , Bernard Lamy , Palaniappa Nanjappan , Radhakrishna K. Pillai , Sibylle Pochon , Bo Song , Rolf E. Swenson
发明人： Philippe Bussat , Samir Cherkaoui , Hong (Helen) Fan , Bernard Lamy , Palaniappa Nanjappan , Radhakrishna K. Pillai , Sibylle Pochon , Bo Song , Rolf E. Swenson
IPC分类号： A61K49/00 , A61B8/00
CPC分类号： A61K49/227 , C07K14/00 , C07K14/52 , Y02A50/58
摘要： Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.
摘要翻译：提供具有高KDR结合亲和力的肽载体和用于制备此类载体的方法。肽载体可以与磷脂结合并包含在超声造影剂组合物中。这样的超声造影剂在治疗和诊断方法中是特别有用的，例如在成像含KDR组织和评估和治疗与肿瘤病症相关的血管生成过程中。本发明还提供大规模生产高纯度二聚体和单体肽磷脂共轭物以及用于形成缀合物的前体材料的方法。本发明还提供了大规模生产含有非常低水平的TFA的高纯度肽磷脂缀合物的方法。

5. 发明授权

US06217849B1 Liposome suspensions as blood pool imaging contrast agents 失效
标题翻译：脂质体悬浮液作为血液池成像造影剂
公开(公告)号：US06217849B1
公开(公告)日：2001-04-17
申请号：US08882351
申请日：1997-06-25
申请人： Hervé Tournier , Bernard Lamy
发明人： Hervé Tournier , Bernard Lamy
IPC分类号： A61B5055
CPC分类号： A61K49/0466 , A61K49/1812 , Y10S977/907 , Y10S977/928 , Y10S977/929 , Y10S977/93
摘要： The present invention concerns injectable blood pool contrast agents for NMR and X-ray imaging purpose. These blood pool agents carry imaging contrast enhancers, e.g. paramagnetic or, respectively, radio-opaque compounds for imaging the circulation and/or circulation targeted organs. The blood pool agent compositions are formulated to protect the contrast agents from early removal by the reticulo-endothelial (RES) system of the liver and the spleen, so that they stay in the circulation long enough to provide good images of the blood vessels and blood perfused organs. X-ray and NMR imaging of the circulation and of targeted organs can strongly assist in diagnosing possible ailments in human and animal patients.
摘要翻译：本发明涉及用于NMR和X射线成像目的的可注射血液池造影剂。这些血液池剂携带成像对比增强剂，例如顺磁性或分别为不透射线的化合物，用于成像循环和/或循环靶向器官。配制血液池剂组合物以保护造影剂免于肝脏和脾脏的网状内皮（RES）系统的早期去除，使得它们在足够长时间内保持在循环中以提供良好的血管和血液图像灌注器官循环和目标器官的X射线和核磁共振成像可以有力地帮助诊断人类和动物患者的可能的疾病。

6. 发明授权

US5833948A Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant 失效
标题翻译：包含含有亲脂性螯合剂和非离子表面活性剂的胶束的血池成像组合物
公开(公告)号：US5833948A
公开(公告)日：1998-11-10
申请号：US663545
申请日：1996-06-13
申请人： Herve Tournier , Bernard Lamy , Roland Hyacinthe
发明人： Herve Tournier , Bernard Lamy , Roland Hyacinthe
IPC分类号： A61K49/00 , A61K49/18 , A61B5/055
CPC分类号： A61K49/1806 , Y10S514/836 , Y10S514/937
摘要： The invention concerns NMR imaging contrast compositions comprising magnetically responsive species coupled to physiologically acceptable amphipatic organic substrate materials in the form of mixed micelles suspended or dispersed in a physiologically acceptable aqueous liquid carrier. The compositions are particularly useful for diagnostic investigations of the blood-pool. The invention also concerns the preparation of the mixed micelles, as well as of injectable compositions containing the mixed micelles as contrast agents for MRI purpose. Once injected, the mixed micelles of the compositions behave as imaging contrast enhancers, e.g. they will improve the quality and resolution of the electronically processed images obtained during MRI examinations of the circulation and/or circulation targeted organs. The compositions are formulated to protect the particles of the contrast agents from early removal by the reticulo-endothelial (RES) system of the liver and the spleen, so that they will stay in the circulation for a time sufficient to properly image the blood vessels and to be transported to selected organs. MRI imaging of the circulation and of targeted organs can strongly assist in diagnosing possible ailments in human and animal patients.
摘要翻译：本发明涉及包含悬浮或分散在生理上可接受的水性液体载体中的混合胶束形式的生理上可接受的两亲性有机底物材料的磁响应物质的NMR成像对比剂组合物。该组合物特别适用于血液池的诊断研究。本发明还涉及混合胶束的制备，以及含有混合胶束作为MRI目的的造影剂的可注射组合物。一旦注射，组合物的混合胶束表现为成像对比增强剂，例如，它们将提高在循环和/或循环目标器官的MRI检查期间获得的电子处理图像的质量和分辨率。配制组合物以保护造影剂的颗粒免于肝脏和脾脏的网状内皮（RES）系统的早期去除，使得它们将停留在循环中足以适当地使血管成像的时间，被运送到选定的器官。循环和目标器官的MRI成像可以有力地帮助诊断人类和动物患者的可能的疾病。

7. 发明授权

US4824578A Method of purifying bioactive substances by biospecific adsorption 失效
标题翻译：通过生物特异性吸附纯化生物活性物质的方法
公开(公告)号：US4824578A
公开(公告)日：1989-04-25
申请号：US23861
申请日：1987-02-05
申请人： Michel Schneider , Christian Guillot , Bernard Lamy
发明人： Michel Schneider , Christian Guillot , Bernard Lamy
IPC分类号： G01N33/48 , B01D15/08 , B01J20/02 , B01J20/22 , B01J20/281 , B01J20/32 , C07F7/18 , C12N9/00 , C12N11/14 , G01N30/88 , B01D15/00
CPC分类号： B01D15/3804 , B01J20/08 , B01J20/103 , B01J20/28004 , B01J20/28057 , B01J20/286 , B01J20/3204 , B01J20/3219 , B01J20/3246 , B01J20/3257 , B01J20/3259 , B01J20/3261 , B01J20/3263 , B01J20/3274 , B01J2220/54 , Y10S977/773 , Y10S977/775 , Y10S977/888
摘要： A ligand specific to a bioactive substance to be purified is fixed, through a connecting silane, to a mineral particulate carrier chosen from among SiO.sub.2, Al.sub.2 O.sub.3, ZrO.sub.2 and TiO.sub.2, the particles of the carrier being submicronic, non-porous and having a large specific surface. The carrier is contacted with an aqueous extract containing the bioactive substances, for the time required for the substance to become specifically fixed to the carrier. The carrier is then separated and the desired bioactive substance is isolated by desorption.
摘要翻译： PCT No.PCT / CH86 / 00081 Sec。 371日期：1987年2月5日 102（e）1987年2月5日PCT PCT 1986年6月4日PCT公布。公开号WO86 / 07281 1986年12月18日。对于待纯化生物活性物质的配体，通过连接硅烷固定到选自SiO 2，Al 2 O 3，ZrO 2和TiO 2中的矿物颗粒载体上，载体的颗粒是亚微米级，非具有大的比表面积。载体与含有生物活性物质的含水提取物接触，使物质特异性固定在载体上所需的时间。然后分离载体，通过解吸分离所需的生物活性物质。

8. 发明申请

US20100158814A1 Fibrin-Binding Peptides and Conjugates Thereof 有权
标题翻译：纤维蛋白结合肽及其缀合物
公开(公告)号：US20100158814A1
公开(公告)日：2010-06-24
申请号：US12517239
申请日：2007-12-11
申请人： Philippe Bussat , Bernard Lamy , Edmund R. Marinelli , Sibylle Pochon , Bo Song , Rolf E. Swenson
发明人： Philippe Bussat , Bernard Lamy , Edmund R. Marinelli , Sibylle Pochon , Bo Song , Rolf E. Swenson
IPC分类号： A61B8/00 , A61K38/16 , A61K38/10 , C07K14/00 , C07K7/08 , A61P7/02 , A61P35/04 , A61P29/00
CPC分类号： A61K49/14 , A61K49/0043 , A61K49/0056 , A61K49/085 , A61K49/124 , C07K7/06 , G01N33/532 , G01N33/574 , G01N33/86 , G01N2500/04
摘要： Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging., etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof.
摘要翻译：提供了与先前已知的纤维蛋白结合肽相比具有高结合亲和力和优异物理特性的纤维蛋白结合肽。这些纤维蛋白结合肽可以缀合到可检测标记或治疗剂，并用于检测和促进治疗与血纤维蛋白如血栓形成和血管生成和肿瘤状况有关的病理状况。这些肽可用于诸如MRI，超声和核医学成像（例如PET，闪烁照相成像等）的成像过程中。肽也可以在治疗上使用。本发明还提供了制备和使用这些肽及其缀合物的方法和方法。

9. 发明授权

US5445810A Injectable opacifying composition containing liposomes of high encapsulating capacity for X-ray examinations 失效
标题翻译：含有X射线检查的高封装能力的脂质体的注射不透明组合物
公开(公告)号：US5445810A
公开(公告)日：1995-08-29
申请号：US128206
申请日：1993-09-29
申请人： Michel Schneider , Herve Tournier , Bernard Lamy
发明人： Michel Schneider , Herve Tournier , Bernard Lamy
IPC分类号： A61K9/127 , A61K9/50 , A61K49/04
CPC分类号： A61K49/0466
摘要： Injectable aqueous composition intended for opacifying certain organs with a view to examination by X-rays. This composition is based on liposomes containing, encapsulated thereein, an aqueous solution of an iodinated opacifying agent. The ratio between the weight of iodine encapsulated by the liposomes and the weight of the lipids from which their membrane is formed is not lower than 1.5 mg/mg.
摘要翻译：可注射的含水组合物用于使某些器官不透明，以便通过X射线检查。该组合物基于含有包封的含有所述碘化不透明剂的水溶液的脂质体。由脂质体包封的碘的重量与其膜形成的脂质的重量之比不低于1.5mg / mg。

10. 发明授权

US08551450B2 Targeting vector-phospholipid conjugates 有权
标题翻译：靶向载体 - 磷脂缀合物
公开(公告)号：US08551450B2
公开(公告)日：2013-10-08
申请号：US12782783
申请日：2010-05-19
申请人： Philippe Bussat , Samir Cherkaoui , Hong (Helen) Fan , Bernard Lamy , Palaniappa Nanjappan , Radhakrishna Pillai , Sibylle Pochon , Bo Song , Rolf E. Swenson
发明人： Philippe Bussat , Samir Cherkaoui , Hong (Helen) Fan , Bernard Lamy , Palaniappa Nanjappan , Radhakrishna Pillai , Sibylle Pochon , Bo Song , Rolf E. Swenson
IPC分类号： A61K49/00 , A61B8/00
CPC分类号： A61K49/223 , A61K38/00 , A61K47/544 , A61K47/60 , A61K47/62 , A61K49/227 , C07K7/08 , C07K14/001 , C07K14/52 , C07K14/71 , C07K2319/00 , Y02A50/58
摘要： Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.
摘要翻译：提供具有高KDR结合亲和力的肽载体和用于制备此类载体的方法。肽载体可以与磷脂结合并包含在超声造影剂组合物中。这样的超声造影剂在治疗和诊断方法中是特别有用的，例如在成像含KDR组织和评估和治疗与肿瘤病症相关的血管发生过程中。本发明还提供大规模生产高纯度二聚体和单体肽磷脂共轭物以及用于形成缀合物的前体材料的方法。本发明还提供了大规模生产含有非常低水平的TFA的高纯度肽磷脂缀合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式